EUVIMEDEUVIMED entdecken
Crossref

Dasatinib inhibits betacoronavirus replication in macrophages and attenuates pro-inflammatory mediators via SRC-MAPK pathway modulation

Ana Carolina Santos Ricoy, Marina Pimenta Braga, Thaís Targino Ferreira Lacerda, Flávia Rayssa Braga Martins, Ana Clara Mendes, Mauro Martins Teixeira, Vivian Vasconcelos Costa, Diana Bahia, Frederico Marianetti Soriani

Medical Microbiology and Immunology · 2025

DOI: 10.1007/s00430-025-00850-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Microbiology and Immunology, 2025. Verfasst von Ana Carolina Santos Ricoy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Genética, Ecologia e Evolução, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, …. Hauptthemen laut MEDLINE: Dasatinib, Virus Replication, Macrophages, src-Family Kinases. Die Arbeit nennt 73 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Betacoronaviruses are emerging pathogens with pandemic potential, as shown by the recent COVID-19 pandemic caused by SARS-CoV-2. The replication of SARS-CoV-2 in monocytes and macrophages triggers the production of cytokines and chemokines, leading to a persistent inflammatory environment associated with increased disease severity. Dasatinib (DASA) is a broad-spectrum tyrosine kinase inhibitor that targets a wide range of tyrosine kinases, including ABL, SRC, c-KIT, PDGFR-α and ß, involved in the pathophysiology of various malignancies. Studies have reported additional mechanisms of action for DASA beyond the oncological context, including anti-inflammatory and antiviral effects. We investigated the potential of DASA as a promising therapeutic approach against betacoronavirus infections. Using an in vitro model of infection of RAW 264.7 cells with MHV-3, a betacoronavirus that mimics severe COVID-19 in murine models, we observed that both pre and post-infection treatment with DASA significantly reduced viral titers and pro-inflammatory mediators, such as IL-6, TNF, and CXCL2. Pre-treatment with DASA interfered with the early stages of the viral cycle in macrophages, such as viral adsorption and internalization, reducing viral titers. We demonstrated that SRC tyrosine kinase signaling is activated during MHV-3 infection. Post-infection treatment with DASA negatively modulated the SRC-MAPK-NF-ĸB signaling pathway, reducing the release of pro-inflammatory mediators by macrophages. Our data suggest the potential use of DASA as a promising adjuvant therapeutic strategy for treating coronavirus infections by negatively modulating SRC-mediated signaling pathways involved in inflammation and reducing MHV-3 replication. The results demonstrated that SRC signaling could be a target for interventions in controlling coronavirus infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DasatinibVirus ReplicationMacrophagessrc-Family KinasesAntiviral AgentsMurine hepatitis virusMAP Kinase Signaling SystemAnimalsMiceRAW 264.7 CellsSARS-CoV-2CytokinesCOVID-19Inflammation MediatorsSignal Transduction

Stichwörter der Autor:innen

Dasatinib (DASA)MAPK signaling pathwayMHV-3 betacoronavirusMacrophagesSrc-family kinases

Substanzen

Dasatinibsrc-Family KinasesAntiviral AgentsCytokinesInflammation Mediators

Autor:innen und Institutionen

  • Departamento de Genética, Ecologia e Evolução, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
  • Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
  • Departamento de Morfologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
  • Departamento de Genética, Ecologia e Evolução, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. fredsori@gmail.com.

Förderung

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

Zitieren

APA

Ricoy, A. C. S., Braga, M. P., Lacerda, T. T. F., Martins, F. R. B., Mendes, A. C., Teixeira, M. M., Costa, V. V., Bahia, D., & Soriani, F. M. (2025). Dasatinib inhibits betacoronavirus replication in macrophages and attenuates pro-inflammatory mediators via SRC-MAPK pathway modulation. Medical Microbiology and Immunology. https://doi.org/10.1007/s00430-025-00850-2

Vancouver

Ricoy ACS, Braga MP, Lacerda TTF, Martins FRB, Mendes AC, Teixeira MM, et al. Dasatinib inhibits betacoronavirus replication in macrophages and attenuates pro-inflammatory mediators via SRC-MAPK pathway modulation. Medical Microbiology and Immunology. 2025. doi:10.1007/s00430-025-00850-2

BibTeX
@article{Ricoy2025,
  author = {Ricoy, Ana Carolina Santos and Braga, Marina Pimenta and Lacerda, Thaís Targino Ferreira and Martins, Flávia Rayssa Braga and Mendes, Ana Clara and Teixeira, Mauro Martins and Costa, Vivian Vasconcelos and Bahia, Diana and Soriani, Frederico Marianetti},
  title = {Dasatinib inhibits betacoronavirus replication in macrophages and attenuates pro-inflammatory mediators via SRC-MAPK pathway modulation},
  journal = {Medical Microbiology and Immunology},
  year = {2025},
  doi = {10.1007/s00430-025-00850-2}
}
Kostenlos starten →